Ignite Creation Date:
2025-12-24 @ 4:15 PM
Ignite Modification Date:
2025-12-29 @ 12:18 AM
Study NCT ID:
NCT05710666
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-08-05
First Post:
2022-12-20
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Neoadjuvant Trastuzumab Deruxtecan (T-DXd) With Response-directed Definitive Therapy in Early Stage HER2-positive Breast Cancer (SHAMROCK Study)
Sponsor:
Cancer Trials Ireland
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-10-26
Start Date Type:
ACTUAL
Primary Completion Date:
2025-09-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-03-30
Completion Date Type:
ESTIMATED
First Submit Date:
2022-12-20
First Submit QC Date:
None
Study First Post Date:
2023-02-02
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-08-02
Last Update Post Date:
2024-08-05
Last Update Post Date Type:
ACTUAL